LIXT

$3.01

Pre-MarketAs of Mar 17, 8:00 PM UTC

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Simply Wall St.
Nov 19, 2025

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.